Celebrex CV Risk v. Naproxen, Ibuprofen: US FDA Does Not Recommend Differential Labeling
Executive Summary
Advisory committee to evaluate whether PRECISION trial shows celecoxib cardiovascular safety is comparable to naproxen and ibuprofen and if naproxen and ibuprofen use should be contraindicated with aspirin.
You may also be interested in...
Celebrex Likely To Get Label Change Saying CV Risk Is Comparable To Ibuprofen, Naproxen
Despite concerns about difference in dosages and study discontinuation rates, US FDA advisory committee concludes that Pfizer's study demonstrated similar CV risk among the three NSAIDs.
Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits?
Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.
Celebrex Should Stay On Market, FDA Panel Says, But Splits On Vioxx, Bextra
Pfizer's COX-2 inhibitor Celebrex can remain on the market with new labeling warnings, including a "black box" about the increased risk of cardiovascular events, an FDA advisory committee recommended Feb. 18